Sage Therapeutics Priced, Nasdaq: SAGE
Developing treatments for life-threatening epileptic seizures.
Industry: Health Care
First Day Return: +67.2%
SAGE
Developing treatments for life-threatening epileptic seizures.
| IPO Data | |
|---|---|
| IPO Date | 07/17/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $90 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Cambridge, MA, United States |
| Founded | 2010 |
| Employees at IPO | 25 |
| Website www.sagerx.com | |
IPO News for Sage Therapeutics
Sage Therapeutics (SAGE) Performance
